3,000 cancer patients to help unlock secrets of drug resistance
NCT ID NCT03572192
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to collect tissue and blood samples from 3,000 adults with solid tumors to learn why cancers spread and become resistant to treatments. Researchers will use advanced lab tests to find molecular defects that drive cancer growth. The goal is to use this knowledge to develop better treatments and tests in the future. Participants will donate samples taken during routine medical procedures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3,000 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
Sep 2013
- Expected to finish
-
Aug 2043
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
solid tumours
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male and female patients over the age of 18 years who have been diagnosed with a solid tumour and who are seen at the Barts Health NHS Trust for clinical management of their tumour. 2. Male or female more than 18 years of age 3. Able to participate in the study. 4. Able to give informed consent. 5. Patients enrolled into other clinical trials may be included into this study Exclusion Criteria 1. Any co-existing medical condition that in the Investigator's judgement will substantially increase the risk associated with the patient's participation in the study 2. Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies 3. Physical or mental health issues that preclude them from participation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Solid tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
St Bartholomew's Hospital
RECRUITINGLondon, EC1A 7BE, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
- Can a new drug shield kidneys from chemotherapy damage?
- Mining Responders' tumors for clues to a universal cancer therapy
- Proton boost radiotherapy aims to hit large tumors harder while sparing healthy tissue
- New antibody aims to preserve immune checkpoint while fighting cancer
- Engineered immune cells target two markers on Hard-to-Treat tumors